Skip to main content

Table 1 Selection criteria for HDACi

From: High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons

Molecule name Selectivity Development status Maximum development phase FDA approved BBB penetration Half-life (h)
Entinostat HDAC 1, 3 Investigational 3 0 Limited/poor 33–150 [63]
JNJ-26481585 Pan HDAC Investigational 2 0 Not reported 8,8 [64]
Pracinostat Pan HDAC Investigational 2 0 Yes in mice 5,6–8,9 [65]
Panobinostat Pan HDAC Marketed 4 1 Limited 16 [66]
Belinostat Pan HDAC Marketed 4 1 Limited 1,5 [67]
Trichostatin A Pan HDAC Investigational 1 0 Limited Not determined
Givinostat Pan HDAC Investigational 3 0 Yes 6,9 [68]
Vorinostat Pan HDAC Marketed 4 1 Yes 1–2 [69]
Abexinostat Pan HDAC Investigational 1 0 Yes 4 [70]
CUDC-101 Pan HDAC, Her, EGFR Investigational 1 0 Not reported 4,4 [71]
Dacinostat Pan HDAC Investigational 2 0 Not reported 6–15 [72]
Mocetinostat Class I selective Investigational 2 0 Yes in mice 7–11 [73]
CUDC-907 Pan HDAC, PI3K Investigational 2 0 < 10% in mice 3 [74]
Resminostat HDAC 1, 3, 6 Investigational 2 0 Not reported 3 [75]
Tacedinaline Class I selective Investigational 3 0 15–45% in monkey 8,5–10 [76]
RG2833 HDAC 1, 3 Investigational 1 0 Yes in mice 6–10 [77]
M344 Pan HDAC Discovery   0 Yes in mice Not determined
Domatinostat Pan HDAC, LSD1 Investigational 1 0 Not reported 20 [78]
Scriptaid Pan HDAC Discovery   0 Not reported Not determined
Rocilinostat HDAC 6 Investigational 2 0 Not reported 3 [79]